AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02527083
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00625729
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 mg/kg intravenous (IV) on Day -5.
Trial: NCT01742052
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01274247
Drug: Topical Benzocaine
RxNorm normalized name: benzocaine Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical administration of a drop of benzocaine to the lingual frenulum
Trial: NCT01656720
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01766089
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil (0.1 µg/kg/min) starting 5 min before induction of anaesthesia and continued until peritoneal closure.
Trial: NCT01171937
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children get randomized to either placebo or risperidone
Trial: NCT01064284
Drug: PLASMA DERIVED Factor VIII
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximum dosage : 50IU per kilo. 2-3 times per week or on demand during acute episode of bleeding
Trial: NCT02677051
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03072849
Drug: FAM Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients who have evidence of early airflow obstruction on pulmonary function testing will be started on FAM therapy. Early airflow obstruction is defined by a FEV1 decline of ≥10% predicted in addition to a FVC \<0.8.
Trial: NCT00694928
Drug: clindamycin phosphate/butoconazole nitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: semi-solid, single dose
Trial: NCT01670149
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT00231465
Drug: ZD1839
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZD1839 will be continued until progression, or until trial closure, whichever comes first.
Trial: NCT00666341
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: Al(OH)3-Placebos with histamine-dihydrochloride analogue Allergen-Adsorbate rPhleum strengthes 1 to 4.
Trial: NCT00902369
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01714388
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1mcg/kg iv dose, followed by 5 minutes ECG recording
Trial: NCT01044693
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule
Trial: NCT00544687
Drug: Karison® Creme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical Karison® Creme (clobetasol-17-propinate 0.05%)
Trial: NCT00544687
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical (placebo)
Trial: NCT02714543
Drug: aloevera juice
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aloevera juice to drink twice daily for 3 months.
Trial: NCT02714543
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: intralesional injection of hydrocortisone 100mg once a week for 6 weeks
Trial: NCT02714543
Drug: antioxidant
RxNorm normalized name: ANTIOXIDANT GS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules SM Fibro (antioxidants) once daily for 3 months.
Trial: NCT01310114
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thawed placebo
Trial: NCT01483430
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule/day (starch), Duration: 8 weeks
Trial: NCT00283985
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 gr/m2 at J1
Trial: NCT00088881
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00088881
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02596893
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04038008
Drug: Diflucan®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diflucan® is manufactured by Fareva Amboise, France (MAH: PFIZER PHARMA PFE GmbH, Germany). Each hard capsule contains 200 mg of fluconazole.
Trial: NCT03106402
Drug: topical bromfenac sodium hydrate
RxNorm normalized name: Bromfenac Sodium
DrugBank: Bromfenac (DB00963)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00926900
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04279769
Drug: CB-280
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CB-280, oral capsule administered twice daily at the assigned dose level for 14 days
Trial: NCT04279769
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsule administrated twice daily at the assigned dose level for 14 days
Trial: NCT01052428
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 100 mg once a day for 2 years
Trial: NCT00092742
Drug: MK0663, etoricoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00092742
Drug: Comparator: Diclofenac sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02729012
Drug: hypertonic saline solution (NACL 3%+NAHCO3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with nebulized hypertonic saline solution (NACL 3%+NAHCO3)
Trial: NCT02773537
Drug: Adductor canal catheter only
RxNorm normalized name: Canalevia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This nerve block is believed to cause numbness only, without any muscle weakness. A catheter remains in place for up to 36 hours after surgery for the purpose of adding additional medication should the patient require it. This technique causes only the front of the knee to be numb
Trial: NCT02336555
Drug: MK-8291
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8291 oral tablets
Trial: NCT02336555
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral tablets
Trial: NCT01366014
Drug: ARRY-371797, p38 inhibitor; oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple dose, single schedule
Trial: NCT01366014
Drug: Placebo; oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT04843839
Drug: Nepafenac 0.1% Oph Susp
RxNorm normalized name: NEPAFENAC 0.1% OPH SUSP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nepafenac 0.1% eye drops - Allergan : Dosage- 1 drop QID for 6 months
Trial: NCT04843839
Drug: Refresh Tears 0.5% Lubricant Eye Drops
RxNorm normalized name: Refresh Tears 0.5% Lubricant Eye Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Refresh Tears 0.5% w/v eye drops - Allergan : Dose- 1 drop QID for 6 months
Trial: NCT01749293
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects in this trial will receive Cyclophosphamide 50 mg/kg IV QD on Days 3 and 4 post-transplant.
Trial: NCT03992482
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline Eye Drops (0.9% NaCl) two times a day for eight weeks
Trial: NCT03636269
Drug: CR845 0.5 mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV CR845 0.5 mcg/kg administered three times/week
Trial: NCT03636269
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV placebo administered three times/week
Trial: NCT02091830
Drug: Paracetamol and nonsteroidal antiinflammatory drug (NSAID)
RxNorm normalized name: codeine and paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02242903
Drug: LY3079514
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT02242903
Drug: LY3079514
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT02242903
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT02242903
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT02105012
Drug: BD MDI 160 µg
RxNorm normalized name: immunoglobulin G, human 160 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide Inhalation Aerosol administered as 2 inhalations BID
Trial: NCT02105012
Drug: BD MDI 80 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide Inhalation Aerosol administered as 2 inhalations BID
Trial: NCT02105012
Drug: Placebo MDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo MDI administered as 2 inhalations BID
Trial: NCT04370847
Drug: Intrathecal Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl 15 μg will be administered in the subarachnoid space
Trial: NCT04370847
Drug: Intravenous Syntocinon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediately after delivery, syntocinon 10 IU will be added to the running crystalloid solution.
Trial: NCT04504669
Drug: AZD8701
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOXP3 antisense oligonucleotide
Trial: NCT02124421
Drug: Adjuvant Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six weeks post-surgery (CRS or CRS/HIPEC) standard combination chemotherapy will be administered every 21 days for 6 cycles
Trial: NCT00128492
Drug: AZLI 75 mg two times a day (BID)/ three times a day (TID)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02728726
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered intravenously at 2 mg/kg after routine reversal of anesthesia is performed and subject is extubated.
Trial: NCT02597361
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo o.d. to match 150mg or 300mg irbesartan tablets
Trial: NCT02533128
Drug: Liberal blood pressure management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocolized hemodynamic management to maintain mean arterial pressure (MAP) \> 60 mmHg
Trial: NCT02533128
Drug: Tight blood pressure management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocolized hemodynamic management to maintain mean arterial pressure (MAP) \> 75 mmHg
Trial: NCT02002195
Drug: FOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin 85 mg/m2 is given as a 2 hours intravenous infusion, concomitant to and S-leucovorin 200 mg/m2, and followed by 5-FU 2,400 mg/m2 as a 46 hours continuous infusion.
Trial: NCT02002195
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1,000 mg twice a day will be administered until disease progression, unacceptable toxicity or treatment refusal by the patient.
Trial: NCT00216658
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03599726
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 5 mg per day for week 1-2 or 5-6
Trial: NCT04156100
Drug: AGEN1223
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGEN1223 is a bispecific antibody.
Trial: NCT04082325
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to Lu AF88434 oral solution, single dose
Trial: NCT04018950
Drug: ETX2514
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion
Trial: NCT00063362
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were assigned in a one to one ratio to adjunctive lamotrigine versus placebo after stratification for illness type (bipolar I versus bipolar II), historical response to lithium (response versus non-response), and length of current exposure to combination treatment with lithium and divalproex (\< 2 months versus ≥ 2 months). During Phase 2, patients were continued on the same doses of lithium and divalproex as during the open-label treatment phase and equal capsules of double-blind lamotrigine or matching placebo were gradually added per a structured dosing schedule up to a minimum dose of 150 mg and a maximum dose of 200 mg per day.
Trial: NCT03194932
Drug: Intrathecal Triple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IT.
Trial: NCT03401580
Drug: Viena II 160/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily
Trial: NCT03401580
Drug: Viena II 190/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily
Trial: NCT03401580
Drug: Viena II 160/12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily
Trial: NCT03401580
Drug: Viena II 190/12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily
Trial: NCT03399747
Drug: Abb-R-CHOP
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Completely Excised LocalizedGastrointestinal CD20 (+) Diffuse Large B-cell Lymphoma~3 Cycles(1 Cycle:4weeks) of Rituximab Plus CHOP (Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy
Trial: NCT01943084
Drug: Norditropin® FlexPro® pen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as a single subcutaneous (s.c., under the skin) dose (4.0 mg) on 2 separate dosing visits (treatment periods). The 2 treatment periods will be separated by a 7-day washout period.
Trial: NCT01943084
Drug: Genotropin Pen®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as a single subcutaneous dose (4.0 mg) on 2 separate dosing visits (treatment periods). The 2 treatment periods will be separated by a 7-day washout period.
Trial: NCT03142334
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT00920270
Drug: antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: conventional parenteral antibiotics
Trial: NCT00298545
Drug: Calcium and Calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium twice daily together with an oral tablet of 1, 25 dihydroxy vitamin D3 (Calcitriol)
Trial: NCT00494988
Drug: insulin NPH
RxNorm normalized name: insulin NPH human isophane
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00113126
Drug: Treatment interruption
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03680131
Drug: EB01 Cream Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle Cream containing 0% EB w/w applied BID
Trial: NCT03680131
Drug: EB01 Cream 0.2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EB01 Cream containing 0.2% EB01 w/w applied BID
Trial: NCT03680131
Drug: EB01 Cream 1.0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EB01 Cream containing 1.0% EB01 w/w applied BID
Trial: NCT03680131
Drug: EB01 Cream 2.0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EB01 Cream containing 2.0% EB01 w/w applied BID
Trial: NCT04331769
Drug: Guideline-Directed Medical Therapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-Directed Medical Therapy
Trial: NCT00989339
Drug: Twenty-four Hour TPN and Saline Infusion
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of Intralipid 20%, ClinOleic 20% or normal saline at 20 ml/hr for 24 hr.
Trial: NCT01392976
Drug: CO-1.01 Formulation A (Aqueous suspension containing 15 mg/mL of drug solubilized in purified phospholipids)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1250 mg/m2 intravenous infusion on Day 1 for Treatment Sequence 1 and Day 8 for Treatment Sequence 2.
Trial: NCT01392976
Drug: CO-1.01 Formulation B (Aqueous suspension containing 30 mg/mL of drug solubilized in purified phospholipids)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1250 mg/m2 intravenous infusion on Day 1 for Treatment Sequence 2 and Day 8 for Treatment Sequence 1.
Trial: NCT01428453
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT00399360
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg twice daily increasing to 850 mg twice daily after 3 Months
Trial: NCT02626520
Drug: 5-fluorouracil and irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI.3 given every 14 days x 4 cycles
Trial: NCT02014844
Drug: 250 mg/m2 aldoxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02014844
Drug: 350 mg/m2 aldoxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01157429
Drug: Placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill by mouth prior to sessions 5-12 of teh 12-session CBT protocol.
Trial: NCT02620865
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02620865
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02571855
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules matching the ACT-541468 formulations
Trial: NCT00821821
Drug: MCI-186
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 1: Edaravone: circa 1000 mg / 72-hour infusion~Cohort 2: Edaravone: circa 2000 mg / 72-hour infusion
Trial: NCT00821821
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort1:circa 1000mg / 72-hour infusion matching placebo~Cohort2:circa 2000mg / 72-hour infusion matching placebo
Trial: NCT04081012
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo group will receive a similar volume of normal saline as a placebo at the same time intervals.
Trial: NCT03882801
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Periods 1 and 2 (7 days each) participants receive 4 tablets of placebo QHS.
Trial: NCT02078609
Drug: LGH447
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LGH447 in patients with AML or MDS
Trial: NCT03015948
Drug: SHR4640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single dose of SHR4640 (n=8) for each dose cohort
Trial: NCT03015948
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single dose of placebo (n=2) for each dose cohort .
Trial: NCT01534715
Drug: IMGN529
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01267136
Drug: Codeine with acetaminophen
RxNorm normalized name: acetaminophen / codeine Oral Tablet [Tylenol with Codeine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid codeine/acetaminophen (Capital® 5mL= 120mg acetaminophen/12 mg codeine) 0.72 mg/kg \[=0.3 mL/kg\] (max. 36 mg) PO Q6h, plus 0.72 mg/kg (max. 36 mg) PO Q3h pro re nata (PRN) (max. of 3 PRN doses/day)
Trial: NCT03194555
Drug: Low-Dose Naltrexone and Acetaminophen Combination
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Twice daily
Trial: NCT02555358
Drug: docetaxel,0xaliplatin,capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: docetaxel 60mg/m2， ivgtt，2h，d1;capecitabine 1000mg/m2 po bid d1-14; oxaliplatin 130mg/m2， ivgtt，2h，d1;q21d
Trial: NCT02555358
Drug: oxaliplatin,capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxaliplatin 130mg/m2， ivgtt，2h，d1;capecitabine 1000mg/m2 po bid d1-14;q21d
Trial: NCT01620047
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl 3 µg/ml continuously infused for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU)through a femoral nerve sheath catheter.
Trial: NCT01620047
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.9% normal saline delivered through a femoral nerve sheath catheter in addition to a continuous intravenous infusion of fentanyl 3 µg/ml via a PCA pump for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
Trial: NCT03194555
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily
Trial: NCT00382863
Drug: Optimal Medical/Device Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal Medical/Device Therapy - For the purpose of the PEERLESS-HF study, optimal medical therapy is defined as the use of ACE inhibitors and Beta blockers in the highest tolerable doses for three months prior to study enrollment, and Optimal device therapy is defined as CRT or CRT-D for at least three months prior to study enrollment, when indicated.
Trial: NCT00292370
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-blind placebo taken with OL paroxetine
Trial: NCT00449787
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen 500mg tablet
Trial: NCT01933516
Drug: GP2013
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GP2013
Trial: NCT00151073
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no